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Summary
Introduction. — Atrial ﬁbrillation is, to date, a major problem of public health with an important
cost in the health care system.
Discussion. — The therapeutic strategies for atrial ﬁbrillation are complex and their outcomes
have been disappointing globally. New ablative techniques have brought important advances
but the patient’s proﬁle has to be taken into account in the choice of the therapeutic strategies.
The renin-angiotensin system plays a major role in the phenomena of remodelling following the
onset of atrial ﬁbrillation.
Conclusion. — Drugs blocking the renin-angiotensin system can have a real place in the
treatment of atrial ﬁbrillation, not only to maintain sinus rhythm but primarily to prevent
cardiovascular accidents in these patients with atrial ﬁbrillation and in some cases to prevent
the occurrence of atrial ﬁbrillation, for example in hypertensive patients.
© 2008 Elsevier Masson SAS. All rights reserved.MOTS CLÉS
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Résumé
Introduction. — La ﬁbrillation atriale est, actuellement, un problème majeur de santé publique
et représente un coût important dans le système de santé.
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place réelle dans le traitement de la ﬁbrillation atriale, non tant pour maintenir le rythme
sinusal que principalement pour prévenir les accidents cardiovasculaires chez ces patients ayant
ou ayant eu de la ﬁbrillation atriale et dans certains cas pour la prévenir, par exemple chez
l’hypertendu.
© 2008 Elsevier Masson SAS. All rights reserved.
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ihe rate of mortality is higher in patients with atrial ﬁb-
illation than in people of the same age who do not have
trial ﬁbrillation [1]. The cost of care for atrial ﬁbrillation
an be estimated at greater than D 3000 per year [2], which
laces a major burden on healthcare systems: D 2.5 billion in
rance and approximately D 25 billion in Europe. The main
ost drivers are hospitalizations (52%), followed by drugs
23%).
Most patients with atrial ﬁbrillation have many comor-
idities, such as hypertension, coronary artery disease,
eart failure, obesity, sleep apnoea syndrome, dyslip-
daemia and atheroma. Atrial ﬁbrillation accounts for
pproximately one third of hospitalizations for cardiac
hythm disturbances. Over the past 10—20 years, there has
een an increase of greater than 60% in hospital admis-
ions for atrial ﬁbrillation in Western countries [3]. In recent
arge studies such as AFFIRM [4], the proportion of hyperten-
ive patients was very high (71%), and 38% of patients had
oronary artery disease, 23% had heart failure and 20% had
iabetes. In the ALFA study [5], the most frequent comorbid-
ty observed was hypertension followed by coronary artery
isease, valvular heart disease and dilated cardiomyopathy.
n the Euro Heart Survey [6], the proportion of hypertensive
atients was greater than 60%.
Nowadays, hypertension plays a major role in the his-
ory of most patients with atrial ﬁbrillation. Consequently,
he renin—angiotensin system has to be taken into account
n the pathophysiology of atrial ﬁbrillation and in its phar-
acological treatment. Hypertension can be considered to
e a comorbidity but also, in many cases, an aetiology of
trial ﬁbrillation, given its effect on diastolic ventricular
unction, which leads to atrial enlargement and, ultimately,
o increased atrial vulnerability.
athophysiological mechanisms of atrial
brillation
rrhythmias may be caused by cellular and/or tissular
echanisms; they may be abnormalities of inﬂux genesis
abnormal automaticity), triggered activity such as early or
elayed after-depolarizations, or abnormalities of excita-
ion spread, such as circus movement re-entry by anatomical
r functional obstacles and reﬂexion re-entry. The possibility
f abnormal automaticity and delayed after-depolarizations
as been demonstrated in the atrium. In most cases, the
t
f
t
‘
iechanism of atrial ﬁbrillation is related to multiple micro
e-entries. Less frequently, the initial mechanism may be an
fter-depolarization or an abnormal automatism. In 1988,
aissaguerre et al. demonstrated that in some cases atrial
brillation is due to abnormal automaticity coming from the
ulmonary veins, with a secondary desynchronization [7].
ther mechanisms, such as rotors, may also interfere. To
ate, many proposals have been made about the intrinsic
ardiac nervous system also playing a role in the perpetua-
ion of atrial ﬁbrillation.
When atrial ﬁbrillation is present, remodelling phenom-
na occur in the atrium: electrical remodelling, contractile
emodelling and, ﬁnally, structural remodelling. More than
0 years ago, we showed that in atrial ﬁbrillation, most of
he action potentials recorded by the microelectrode tech-
ique in the human atrium have a triangular shape and
short cellular refractory period [8]. This shortening of
ction potential duration is a factor of arrhythmia but may
lso be a consequence of the arrhythmia itself. Indeed,
ijffels et al. demonstrated clearly that atrial ﬁbrillation
egets atrial ﬁbrillation [9]. In other words, the occurrence
f atrial ﬁbrillation induces a reduction in action poten-
ial duration, a reduction in refractory periods and a loss
f the adaptation of these refractory periods to the heart
ate.
Much of the research into this ﬁeld of remodelling has
hown the occurrence of current modiﬁcations in atrial ﬁb-
illation. Electrical remodelling leads to a decrease in action
otential duration and in wavelength (which is the prod-
ct of the refractory period and the conduction velocity).
hese modiﬁcations also result in contractile remodelling,
ith a decrease in cytosolic calcium, contractility, dilatation
nd, ﬁnally, stretch of the atrium. Structural remodelling
nvolving connexins has also been observed, inducing ﬁbro-
is, which is responsible for anisotropy, zigzag conduction
nd, ultimately, multiple micro re-entries (Fig. 1) [10].
Fibroblast activation and collagen accumulation also
ccur during structural remodelling [11]. Drugs such
s angiotensin-converting enzyme inhibitors, angiotensin II
eceptor blockers and spironolactone are capable of lim-
ting this accumulation, that is, modifying the evolutionJ.-Y. Le Heuzey et al.
iscussion. — Le traitement de la ﬁbrillation atriale reste complexe et pour certains patients
elativement décevant. Les nouvelles techniques ablatives ont apporté des avancées notables,
ais le proﬁl pathologique du patient reste un élément majeur dans le choix des straté-
ies thérapeutiques. Le système rénine angiotensine joue un rôle de premier plan dans les
hénomènes de remodelage qui suivent l’installation de la ﬁbrillation atriale.
onclusion. — Les médicaments qui bloquent le système rénine angiotensine peuvent avoir uneowards remodelling and ﬁbrosis. This is the rationale
or the potential beneﬁcial effect of drugs that block
he renin—angiotensin system, in what is currently called
upstream’ therapy. The goal of this therapeutic approach
s to limit the structural remodelling of the atrium in atrial
Pathophysiology of atrial ﬁbrillation: Insights into the renin—ang
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itself), the patients treated with angiotensin-convertingFigure 1. Electrical, contractile and structural remodelling
occurring in atrial ﬁbrillation [10].
ﬁbrillation but also, if possible, to have a preventive effect
on the occurrence of atrial ﬁbrillation in at-risk patients,
such as those with hypertension, coronary artery disease or
heart failure.
Therapeutic implications
The treatment of atrial ﬁbrillation remains complex and is
sometimes disappointing. There are many goals when treat-
ing atrial ﬁbrillation:
• to suppress symptomatology;
• decrease symptoms;
• make symptoms more acceptable;
• improve quality of life;
• decrease professional absenteeism;
• improve exercise performance;
• decrease the burden of atrial ﬁbrillation;
• increase time to ﬁrst recurrence;
• avoid thromboembolic accidents;
• avoid progressive cognitive cerebral deterioration;
• avoid progression towards chronicity;
• maintain physiological rhythm;
• preserve the haemodynamic role of the atrial systole;
• prevent the occurrence of heart failure and increase life
expectancy.
It is not possible to achieve all these goals with only one
drug. In fact, four major objectives have to be achieved:
• an improvement in symptoms and quality of life;
• the avoidance of heart failure;
• the avoidance of thromboembolic accidents and;
• an increase in life expectancy.
In most cases, restoration and maintenance of sinus
rhythm is not the only objective that is worth achieving in
the treatment of atrial ﬁbrillation. As atrial ﬁbrillation is
often considered to be not only an indicator of poor prog-
nosis but also a marker of poor cardiovascular condition,
its treatment also aims to decrease cardiovascular events.
Hence, drugs that block the renin—angiotensin system may
have an important role to play in the therapeutic approach
to atrial ﬁbrillation.
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In 1999, Pedersen et al. published a posthoc analy-
is of the TRACE trial [12], which evaluated trandolapril
ersus placebo in postmyocardial infarction patients with
ow ejection fraction (mean 33%); the authors reported a
educed risk of atrial ﬁbrillation in the group treated with
randolapril. The LIFE trial was published in 2002, com-
aring atenolol and losartan in hypertensive patients [13];
posthoc analysis by Wachtell et al. showed that cardio-
ascular morbidity and mortality in hypertensive patients
ith a history of atrial ﬁbrillation were lower in the
roup who received losartan [14]. Similarly, Watchell et
l. also demonstrated that angiotensin II receptor block-
de reduced new onset atrial ﬁbrillation and subsequent
trokes compared with atenolol [15]. A favourable effect of
ngiotensin-converting enzyme inhibitors was also reported
n a publication by Vermes et al. in 2003, in which the results
f the different SOLVD trials were analysed; the authors
oncluded that enalapril decreases the incidence of atrial
brillation in patients with left ventricular dysfunction [16].
It is difﬁcult to believe that drugs that block the
enin—angiotensin system can have a direct antiarrhyth-
ic effect. However, in a small group of patients (n = 154),
adrid et al. showed that sinus rhythm maintenance after
onversion from persistent atrial ﬁbrillation was superior
n patients who received amiodarone plus irbesartan than
n patients who received amiodarone alone [17]. In the
al-HeFt study, published in 2005, Maggioni et al. showed
hat valsartan was able to reduce the incidence of atrial
brillation in patients with heart failure [18]. Comparable
esults have been obtained in the CHARM trials: alterna-
ive, added and preserved [19,20]. More recently, Fogari et
l. demonstrated the usefulness of losartan in the preven-
ion of atrial ﬁbrillation recurrence in hypertensive patients
21]. This approach to atrial ﬁbrillation prevention is very
nteresting and is considered nowadays to be a beneﬁcial
trategy. Concerning the maintenance of sinus rhythm, Ueng
t al. have shown that enalapril can facilitate sinus rhythm
aintenance after external cardioversion of long-standing,
ersistent atrial ﬁbrillation [22].
All these data are concordant, although a trial designed
peciﬁcally to demonstrate this theory has yet to be been
ublished. The ACTIVE trial [23] will perhaps give the answer
eﬁnitively. ACTIVE is a complex study testing different
ntithrombotic regimens for atrial ﬁbrillation: clopidogrel
lus aspirin versus a vitamin K antagonist and clopido-
rel plus aspirin versus aspirin alone. Some of the patients
ncluded in these arms have also been included in a trial
esting irbesartan versus placebo, according to a factorial
esign. The goal is not to demonstrate better maintenance
f sinus rhythm but to analyse the occurrence of cardio-
ascular events such as stroke, myocardial infarction and
ascular death.
All these small trials or posthoc analyses of large trials
ere studied in a meta-analysis published by Healey et al.
Fig. 2) [24], which demonstrated that regardless of the
eason for inclusion in the different studies (heart failure,
ypertension, postmyocardial infarction or atrial ﬁbrillationnzyme inhibitors and angiotensin receptor blockers had less
requent episodes of atrial ﬁbrillation. Many explanations
an be proposed for this favourable outcome: an effect on
trial pressure, on kaliemia, on left ventricular hypertrophy
790 J.-Y. Le Heuzey et al.
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[igure 2. Meta-analysis of atrial ﬁbrillation prevention with angi
24].
nd left atrial size and pressure, on atherothrombosis
nd coagulation, and, of course, on atrial remodelling as
escribed previously. Drugs blocking the renin—angiotensin
ystem are especially interesting to use in atrial ﬁbrillation
atients with hypertension and heart failure [25].
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